Grifols, S. A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions.
Grifols Sa stock last closed at $9.08, down 0.66% from the previous day, and has increased 36.75% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.47 percentage points. Grifols Sa stock is currently +46.69% from its 52-week low of $6.19, and -8.84% from its 52-week high of $9.96.
There are currently 687.55M GRFS shares outstanding. The market capitalization of GRFS is $6.24B. In the past 24 hours, 191,000 GRFS shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy GRFS stock.
In our opinion, eToro is the best stock brokerage. Here's why:
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the right brokerage, the next step is to fill out some personal details so you can buy GRFS stock today.
Now that you have finished signing up on app for stock, your next step is to transfer the money for your investment:
Watch the video below to see the process of transferring funds into your new investment account.
Once you have chosen the best place to buy Grifols Sa stock, it's very important to analyze their stock before you buy, so you actually wrap your head around the risk and opportunity.
WallStreetZen was created to help everyday investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on GRFS's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge GRFS's intrinsic value.
Using relative valuations metrics:
You can do additional valuation analysis on GRFS's stock here.
Out of 1 sell side analysts who give recommendations on GRFS, the consensus analyst rating on Grifols Sa is a Hold
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Grifols Sa stock forecast page.
Last year, GRFS earnings were $174.36M. In the last 5 year, GRFS's earnings have increased by -25.16% per year. This was slower than the Drug Manufacturers - General industry average of 7.23%.
Last year, GRFS revenue was $8.01B. Over the past 5 year, GRFS's revenue has gone up by 5.57% per year. This was slower than the Drug Manufacturers - General industry average of 9.58%.
You can analyze GRFS's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at GRFS have not bought or sold any shares.
Dig into more about who owns GRFS stock here.
No, Grifols Sa doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
There are two primary options:
Press the Open Trade button and eToro will place the order.
If you need additional help with investing in stocks on eToro, click the how to video below:
Now that you own some GRFS stock, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to get the latest updates about your GRFS stock.
To reiterate, here are the 6 steps you need to take to buy Grifols Sa stock right now:
If you are looking for a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest news on your investment in Grifols Sa, get started below.